Download Adjuvant chemotherapy in NSCLC

Document related concepts
no text concepts found
Transcript
Adjuvant chemotherapy in NSCLC
종양혈액내과
이재진
우리나라 암발생률
1999-2001
보 건 복 지 부
2005. 4. 27
암 발생 통계
연도
남자
여자
계
1999년
57,687
43,202
100,889
2000년
57,417
43,050
100,467
2001년
61,927
47,432
109,359
계
177,031
133,684
301,715
연평균발생건수
59,010
44,561
103,571
성별 암종별 발생분율
남자
여자
기타
16.7%
위
23.7%
비호지킨 림프종
2.1%
전립선
2.4%
위
16.4%
기타
18.7%
췌장
2.5%
췌장
2.7%
난소
3.0%
담낭
2.7%
담낭
3.5%
2
식도
2.8%
방광
3.1%
대장
9.8%
폐
17.0%
유방
13.7%
갑상선
6.7%
5
간
7.3%
간
17.0%
폐
8.0%
대장
10.4%
자궁경부
9.8%
Incidence and Survival of Lung Cancer
2002년 한국중앙암등록본부
위
20.2%
기타
21.9%
폐
20.0%
기타
20.5%
자궁경부
1.6%
방광
2.2%
폐
11.9%
췌장
2.4%
조혈계
2.6%
수막, 뇌 및 기타 중
추신경계
1.9%
유방
2.2%
위
18.7%
백혈병
2.3%
자궁경
4.0%
식도
2.4%
갑상선
4.9%
유방
7.4%
간
11.3%
대장
11.2%
2002년, 발생율 †
췌장
4.6%
대장
8.1%
간
17.7%
2002년, 사망분율 ‡
Screening test for early detection of Lung caner
• Low dose chest CT
• Sputum cytology
• Chest X-ray
Disease stage at diagnosis of Lung caner
Disease stage at diagnosis
5-year survival
To improve the survival of lung cancer,
Minimize the relapse of lung cancer
at curative setting
Rationale for adjuvant chemotherapy
- Disease recurrence
Stage
Chest
Distant
Stage I
55-65 %
T1N0
10 %
15 %
T2N0
10 %
30 %
Stage II
T1-2N1
40-55 %
12 %
40 %
Stage IIIA
N2
5YS
20-25 %
15 %
60 %
Feld 1984; Pairolero 1984; Mqrtini 1980; Thomas 1990
Rationale for adjuvant chemotherapy
- Theoretical premises
• An inverse relationship between cell number and curability
– Skipper HE et al. Cancer Chemother Res 1964;35:1
• Larger fractional kill in smaller tumors that have larger
growth fraction
– Norton LA. Cancer Res 1988;48:7067
• Drug resistant cells emerge as tumor burden increases
– Goldie JH et al. Cancer Treat Rep 1979;63:1727
Rationale for adjuvant chemotherapy
- Theoretical premises
(Mo)
(Mo)
Cancer medicine 6th edition
Rationale for adjuvant chemotherapy
- Theoretical premises
Systemic therapy
will be
more effective
in the setting of
minimal residual tumor
Survival benefit of adjuvant chemotherapy
in other solid tumors
• Early breast cancer
– 3.2% at 5Y, 6.3% at 10Y
• Early ovarian cancer
– 8% at 5Y
• Duke’s class C colon cancer
– 5% at 3Y
• Limited stage SCLC (by RT & PCI)
– 5.4% at 3Y
Evidence-based medicine
Level and Grade of evidence for recommendations
Clinical trial of Adjuvant chemotherapy
0.
A British Medical Research Council, NSCLC Collaborative Group
–
Meta-analysis, N=4457, 17 trials (BMJ 1995;311:899-909)
–
Nonsignificant 5 percent absolute increase (stage I,II,III) (p=0.08)
1.
2.
3.
4.
5.
6.
The International Adjuvant Lung Cancer Trial (IALT)
The Adjuvant Lung Project Italy-EORTC (ALPI)
The Adjuvant Navelbine International Trialist Association (ANITA)
The Big Lung Trial (BLT)
National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) JBR.10 trial
Lung Adjuvant Cisplatin Evaluation (LACE)
–
7.
8.
Meta-analysis, N=4584, 5 trials (2006 ASCO Annual Meeting)
CALGB protocol 9633 trial/ CALGB protocol 9633 trial
The Japanese Lung Cancer Research Group
Concern in adjuvant setting
• Elderly patients
• Surgery type, i.e., pneumonectomy
• Adjuvant RT
• What regimen
• Compliance, i.e., planned dose
The International Adjuvant Lung Cancer Trial (IALT)
• The effect of cisplatin-based adjuvant CTx on survival ?
– 3 or 4 cycles of cisplatin-based CTx vs. observation
• Etoposide, vinorelbine, vinblastine, vindesine
– 1867 pts: 932 pts (CTx) vs.935 pts (Obs)
• Stage I, stage II, stage III
• 1995/2 - 2000/12/31
• European
• Early termination (N=3,300 pts) d/t slow enrollment ← neoadjuvant CTx
NEJM 2004;350:351-60
The International Adjuvant Lung Cancer Trial (IALT)
NEJM 2004;350:351-60
The International Adjuvant Lung Cancer Trial (IALT)
Median F/U: 56 months
5Y OS: 44.5% vs. 40.4%
5Y DFS: 39.4% vs. 34.3%
Overall survival
Disease free survival
HR 0.86
HR 0.83
Survival Benefit (+)
(95% CI, 0.76-0.98, p<0.03)
(95% CI, 0.74-0.94, p<0.003)
NEJM 2004;350:351-60
The International Adjuvant Lung Cancer Trial (IALT)
• Compliance
– Planned dose: 73.8% of pts
– The chief reasons for incomplete treatment
• Adverse effects: 51.5%
• Pts or physician’s refusal: 24.3%
• PD: 5.1%
– Adjuvant RT; 31% of pts
• Planned therapy: 70.4% in chemotherapy vs. 84.2% in control group
• Acute adverse effects
– Treatment-related death: 0.8% (7pts)
• BM aplasia, renal failure, hyponatremia
– Any grade 4 toxicity: 22.6% of the patients
NEJM 2004;350:351-60
The Adjuvant Lung Project Italy-EORTC (ALPI)
• The effect of cisplatin-based adjuvant CTx on survival ?
– 3 cycles of cisplatin-based CTx vs. observation
• mitomycin, vindesine, cisplatin (MVP regimen)
– 1209 pts: 606 pts (CTx) vs. 603 pts (Obs)
• Stage I, II, IIIA
• 1994/1-1999/1
• European
J Natl Cancer Inst 2003;95:1453-61
The Adjuvant Lung Project Italy-EORTC (ALPI)
J Natl Cancer Inst 2003;95:1453-61
The Adjuvant Lung Project Italy-EORTC (ALPI)
Median F/U: 64.5 months
5Y survival benefit: 1%
5Y DFS benefit: 4%
Median; 55.2m vs. 48m
Median; 36.5m vs. 28.9m
Overall survival
Disease free survival
HR 0.96
HR 0.89
Survival Benefit (-)
(95% CI, 0.81-1.13, p=0.589)
(95% CI, 0.76-1.03, p=0.128)
J Natl Cancer Inst 2003;95:1453-61
The Adjuvant Lung Project Italy-EORTC (ALPI)
• Compliance
– Planned dose: 69% of pts
– The chief reasons for incomplete treatment, 110 pts (22%)
• Adverse effects: 60%
• Pts refusal: 40%
– Adjuvant RT; 43% of pts
• 65% in chemotherapy vs. 82% in control group
• Acute adverse effects
– Treatment-related death: 0.5% (3pts)
– Grade 3/4 neutropenia: 16%/12% of the patients
– Grade 3/4 N/V: 13%/4% of the patients
J Natl Cancer Inst 2003;95:1453-61
ANITA Trial
• The effect of cisplatin-based adjuvant CTx on survival ?
– 4 cycles of vinorelbine plus cisplatin vs. observation
– 840 pts: 407 pts (CTx) vs. 433 pts (Obs)
• Stage IB, stage II, stage IIIA
• 1995/2 - 2000/12/31
• European
Lancet Oncol 2006;7:719-27
ANITA Trial
Lancet Oncol 2006;7:719-27
ANITA Trial
Median F/U: 76 months
5Y OS: 8.6% benefit
0
20
40
60
80
5Y DFS: 8.7% benefit
100 (M)
Overall survival
Disease free survival
HR 0.80
HR 0.76
Survival Benefit (+)
(p=0.017)
(p=0.002)
Lancet Oncol 2006;7:719-27
ANITA Trial
• Compliance
– Planned dose: 50% of pts
• Dose intensity; vinorelbine (59%), cisplatin (89%)
• 3 or more cycles: 61% of pts
– Adjuvant RT; 28% of pts
• Acute adverse effects
– Treatment-related death: 2% (7pts)
– G3/4 toxicity: fatigue (28%), nausea (27%), FN (9%), neuropathy (3%)
Lancet Oncol 2006;7:719-27
Big Lung Trial (BLT)
• The effect of cisplatin-based adjuvant CTx on survival ?
– 3 cycles of cisplatin-containing regimen vs. observation
• Vindesine, mitomycin & ifosfamide, mitomycin & vinblastine, vinorelbine
– 381 pts: 192 pts (CTx) vs. 1893 pts (Obs)
• Stage IB, stage II, stage III, stage IV
• Adjuvant setting, 97% (neoadjuvant setting 3%)
• 1995/11 - 2001/11
• UK
• Early closure d/t slow accrual & ceased funding
Eur J Cardiothorac Surg 2004;26:173-82
Big Lung Trial (BLT)
• Complete resection
Extra information;
R0, 15 pts
R1, 21 pts
R2, 8 pts
True complete resection rate: 95%
• Median duration to start of CTx: 7 wks
Eur J Cardiothorac Surg 2004;26:173-82
Big Lung Trial (BLT)
Median F/U: 34.6 months
2Y OS: 58% vs. 60%
Median, 33.9m vs. 32.6m
2Y DFS: 53% vs. 51%
Median, 27m vs. 24.7m
(Mo)
(Mo)
Overall survival
Disease free survival
HR 1.02
HR 0.97
Survival Benefit (-)
(p=0.90)
(p=0.81)
Eur J Cardiothorac Surg 2004;26:173-82
Big Lung Trial (BLT)
• Compliance
– Planned dose: 64% of pts
• 21% of pts: early termination
– Cause: pts’ and physician decision (49%), toxicity (34%), death, PD
• 13% of pts: no chemotherapy
– Cause: death, refusal, poor condition
– Adjuvant RT; 14% of pts
• Acute adverse effects
– Treatment-related death: 3.1% (6pts)
– Any G3/4 toxicity: 30%, hematologic, N/V, FN
Eur J Cardiothorac Surg 2004;26:173-82
NCIC CTG JBR. 10 trial
• The effect of adjuvant vinorelbine plus cisplatin on survival ?
– 4 cycles of vinorelbine plus cisplatin vs. observation
– 482 pts: 242 pts (CTx) vs. 240 pts (Obs)
• Stage IB, stage II (except, T3N0)
• 1994/4 - 2001/4
• CALGB, SWOG, ECOG joined in 1998
• Canadian and American
NEJM 2005;352:2589-97
NCIC CTG JBR. 10 trial
NEJM 2005;352:2589-97
NCIC CTG JBR. 10 trial
Median F/U: 63 months
5Y OS: 69% vs. 54%
5Y DFS: 61% vs. 49%
Overall survival
Disease free survival
HR 0.69
HR 0.60
Survival Benefit (+)
(p=0.009)
(p<0.001)
NEJM 2005;352:2589-97
NCIC CTG JBR. 10 trial
7% benefit
20% benefit
NEJM 2005;352:2589-97
NCIC CTG JBR. 10 trial
• Compliance
– Planned dose: 48% of pts
• Median cycle: 3
• 3 or more cycles: 58% of pts
– 32% of patients required hospitalization
• 7% for chemotherapy
• 6% for unrelated treatment
• 19% for medical problem related to toxicity
– Adjuvant RT (-)
• Acute adverse effects
– Treatment-related death: 0.8% (2pts)
– G3/4 toxicity: fatigue (15%), nausea (10%), FN (7%)
– G3/4 neurotoxicity: hearing loss (2%), sensory & motor (5%)
NEJM 2005;352:2589-97
Lung Adjuvant Cisplatin Evaluation (LACE)
• Meta-analysis
– 5 Randomized Trials
– 4,584 patients
– Inclusion
• Sample size >300
• Cisplatin-based chemotherapy
– Median F/U; 5.1 years (3.1-5.9)
2006 ASCO Annual Meeting
Lung Adjuvant Cisplatin Evaluation (LACE)
Overall survival
HR 0.89 (p=0.004)
Survival Benefit (+)
2006 ASCO Annual Meeting
Lung Adjuvant Cisplatin Evaluation (LACE)
3.9%
5.3%
Overall survival
Survival Benefit (+)
2006 ASCO Annual Meeting
Lung Adjuvant Cisplatin Evaluation (LACE)
Cisplatin-based chemotherapy is effective for stages II & III
2006 ASCO Annual Meeting
Lung Adjuvant Cisplatin Evaluation (LACE)
The effect of cisplatin + vinorelbine was marginally better than
that of other drug combination (p=0.04, post-hoc analysis)
2006 ASCO Annual Meeting
CALGB protocol 9633 trial
• The effect of adjuvant paclitaxel plus carboplatin on survival ?
– 4 cycles of paclitaxel plus carboplatin vs. observation
– 344 pts: 173 pts (CTx) vs. 171 pts (Obs)
• Stage IB
• 1996/9 - 2003/11
• American
• Early closure d/t slow accrual & ceased funding
JCO 2004;22:14S, ASCO abstract
JCO 2006;24:18S, ASCO abstract
CALGB protocol 9633 trial
• Patients’ characteristics
– Age; 61 yr (34-81)
– M;F=64%;36%
– Surgery
• Lobectomy; 89%
JCO 2004;22:14S, ASCO abstract
JCO 2006;24:18S, ASCO abstract
CALGB protocol 9633 trial
Median F/U: 34 months
3Y OS: 79% vs. 71%
Overall survival
HR 0.62
(p=0.028)
Median F/U: 54 months
5Y OS: 59% vs. 57%
Overall survival
HR 0.80
(p=0.32)
Disease free survival
HR 0.69
(p=0.035)
Disease free survival
HR 0.74
(p=0.027)
Survival Benefit (+)
Survival Benefit (-)
JCO 2004;22:14S, ASCO abstract
JCO 2006;24:18S, ASCO abstract
CALGB protocol 9633 trial
3Y OS: 79% vs. 71%
5Y OS: 59% vs. 57%
Survival Benefit (+)
Survival Benefit (-)
JCO 2004;22:14S, ASCO abstract
JCO 2006;24:18S, ASCO abstract
CALGB protocol 9633 trial
Survival Benefit (+)
DFS Benefit (+)
JCO 2004;22:14S, ASCO abstract
JCO 2006;24:18S, ASCO abstract
CALGB protocol 9633 trial
• Compliance
– Planned cycle: 84% of pts
– 33% of patients required dose modification
• Acute adverse effects
– Treatment-related death: 0%
– G3/4 neutropenia; 36% of pts
JCO 2004;22:14S, ASCO abstract
JCO 2006;24:18S, ASCO abstract
The Japanese Lung Cancer Research Group
• The effect of Uracil-tegafur adjuvant CTx on survival ?
– oral uracil-tegafur for 2 years vs. observation
– 979 pts: 491 pts (CTx) vs.488 pts (Obs)
• pT1N0, pT2N0 (stage I)
• Adenocarcinoma
• 1994/1 - 1997/3
NEJM 2004;350:1713-21
The Japanese Lung Cancer Research Group
NEJM 2004;350:1713-21
The Japanese Lung Cancer Research Group
Median F/U: 73 months
5Y OS: 88% vs. 85%
5Y OS: 85% vs. 74%
Overall survival
Overall survival with T2 disease
HR 0.71
HR 0.48
Survival Benefit (+)
(p=0.04)
(p=0.005)
NEJM 2004;350:1713-21
The Japanese Lung Cancer Research Group
• Compliance
– Planned dose: 74% of pts at 1Y, 61% at 2Y
– The chief reasons for incomplete treatment
• Adverse effects: 123 pts
• Patient’s refusal: 52 pts
• Physician’s decision: 34 pts
• Acute adverse effects
– Any grade 3 toxicity: 2% of the patients
• Anorexia, nausea, diarrhea, increase of ALT
NEJM 2004;350:1713-21
Phase III trial
Trial
When
N
Regimen
RT
Stage
31
%
I,II,III
4.1%
Nation
TRD
Subgroup
analysis
<0.03
Europe
0.8%
-
5YS (+) P-value
IALT
95
1867
P+
VNR,VBL,
VDS,VP-16
ALPI
94
1209
P+
MMC+VDS
43
%
I,II,III
1%
0.589
Europe
0.5%
-
ANITA
95
840
P+
VNR
28
%
IB,II,IIIA
8.6%
0.017
Europe
2%
N1,N2 (+)
BLT
95
381
P+
VDS,MI,
MV,VNR
14
%
IB,II,III
2Y,
-2%
0.90
UK
3.1%
-
JBR.10
94
482
P+
VNR
-
IB,II
15%
0.009
Canada
USA
CALGB
96
344
CbTx
-
IB
3Y,8%
5Y,2%
0.028
0.32
USA
0%
T>4cm(+)
Japan
94
979
Tegafur
-
I,adenoca
3%
0.04
Japan
0%
T2(+)
0.8% Stage II(+)
Survival benefit
• Worldwide
75세 미만; 900,000/yr, Lung cancer Dx
 80% NSCLC; 720,000
 1/3 resectable; 240,000
 75% adjuvant chemotherapy Ix: 180,000
 4% survival benefit; 7000/yr safe
• 한국
75세 미만; 11,000/yr, Lung cancer Dx
 80% NSCLC; 9,000
 1/3 resectable;3,000
 75% adjuvant chemotherapy Ix: 2,500
 4% survival benefit; 100/yr safe
Standard therapy of resectable NSCLC
Harrison, 16th Edition:
• Surgical resection for stage IA, IB, IIA, IIB, some IIIA
• Surgical resection with complete-mediastinal LN dissection
RecommendofCisplatin-based
chemotherapy
stage II &patients
III NSCLC.
• Discussion
risks/benefits adjuvant
of adjuvant
Ctx withinfor
individual
 Consider cisplatin-based adjuvant chemotherapy for stage IB.
- size, age, surgery type etc.
Limitation
• Compliance
– Age, pneumonectomy
• QoL
– Fatigue, N/V
• A large proportion of patients with cancer
– without any benefit
• Toxic effects of treatment
– TRD: below 1.0 %
Major issue of adjuvant chemotherapy
• Poor compliance
– LCSG 772: cumulative dose: 58% of the scheduled dose
– LCSG 791: only 51% of pts as scheduled dose
– NCIC CTG BR.10: only 50% of pts as scheduled dose
Lung Cancer 2005;47:385-94
Compliance of adjuvant chemotherapy
Lung Cancer 2005;47:385-94
평균수명까지 생존 시 암에 걸릴 확률은 ?
평균수명
(2000년)
암에 걸릴 확률
72.8세
80.1세
74세까지
누적위험
29.0%
80세까지
누적위험
20.2%
약 3명 중 1명
약 5명 중 1명
Major issue of adjuvant chemotherapy
• Adjuvant chemotherapy in elderly patients, NCIC-CTG JBR.10
– West
• >65 years: more than 50%
• >70 years: 30-40%
– Korea
>65 years: 54.7%
>70 years: 34.0%
JCO 2007;25:1553-61
Adjuvant chemotherapy in elderly patients
JCO 2007;25:1553-61
Adjuvant chemotherapy in elderly patients
Overall survival, age> 65 years
JCO 2007;25:1553-61
Impact of adjuvant chemotherapy in Elderly patients
• Adjuvant CTx improves survival in patients older than 65 years
with acceptable toxicity
• Adjuvant CTx should not be with held from elderly patients
QoL of adjuvant chemotherapy
• NCIC CTG BR.10 with EORTC QLQ-C30
– Observation arm: improvement in QoL by 3 months
– Chemotherapy arm: Rapidly resolved within 3 months after completion of CTx
80
70
60
50
40
30
20
10
0
Global QoL
Role function
Physical
function
fatigue
pain
dyspnea
sleep
cough
• BLT with EORTC QLQ-C30
shortness of
breath
worry about
health
Baseline (post-op)
– No evidence to suggest a detrimental effect on QoL from the use of CTx
• LCSG 801, 853 with FLIC (functional living index-C)
Impact of adjuvant chemotherapy on QoL
• No significant impact of a short course of chemotherapy on QoL
• If any side effect, rapidly resolved
Conclusion
• Recommend adjuvant chemotherapy for stage II and III
• Consider adjuvant chemotherapy for stage IB
– Especially, T>4cm
• Elderly patients are no contraindication for adjuvant chemotherapy
• QoL may be rapidly resolved by 3 months after adjuvant therapy
Related documents